Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) asked the FDA to not allow companies to compound GLP-1 semaglutide. This ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Shares of social media companies Reddit (RDDT) and Snap (SNAP) are surging after better-than-expected quarterly results ...

Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Cherny from Leerink Partners reiterated a Hold rating on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day HIMS -1.10% DJIA -0.90% S&P 500 -1.86% Retail/Wholesale -0.53% ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.